Oxford Biomedica Provides
Update on CDMO Services Including New Commercial
Agreement
- New and expanded contracts
highlight commercial momentum across all viral vector
types
- OXB now working on multiple
late-stage programmes with its portfolio of client programmes
progressing to later stage work
Oxford, UK - 20, March, 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or
"the Company"), a quality and innovation-led cell and gene therapy
CDMO, today provides an update on its CDMO services
activity.
Year to date,
Oxford Biomedica has experienced consistently
strong demand for its CDMO services across all key
viral vector types, with its portfolio of
client
programmes transitioning
towards later
stage work. As a result of commercial
developments set out below, OXB is now working on three late-stage
programmes.
Recently, the
Company signed a contract with a new undisclosed
US-based biotechnology company for the manufacture
of lentiviral vectors as the
client prepares for the commercial launch of its CAR-T programme targeting
multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based
manufacturing facility.
Alongside this,
Oxford Biomedica has signed
two new programmes with existing
clinical-stage clients for
projects including Process
Development and GMP
manufacturing.
Furthermore, the Company has signed
a new agreement with a US-based client specialising in cardiac gene
therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV).
Under the terms of
these agreements, Oxford Biomedica will receive
payments related to the development and manufacturing of viral
vectors for use in clinical trials in
addition to certain development and
regulatory milestone payments. These payments will support
the Company in
achieving its medium-term financial guidance announced on
5 March 2024.
Dr
Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica,
commented: "The signing of a late-stage
programme, alongside the continued expansion of existing agreements
since the start of 2024, demonstrates clients' confidence in OXB's
ability to deliver process development and GMP manufacturing
services. Our Business Development team continues to experience
strong demand for process characterisation, validation, and process
performance qualification (PPQ) work, showcasing the high quality
and reliability of our services. This demand is in line with our
forecasts across all key vectors and geographies, validating our
growth strategy. We remain confident about our future prospects as
the leading global pure-play CDMO in cell and gene therapy and our
ability to continue building our client
portfolio."
-Ends-
Enquiries:
Oxford Biomedica
plc:
Sophia Bolhassan, VP, Corporate Affairs and IR - T:
+44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led cell and gene therapy contract
development and manufacturing organisation (CDMO) with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original pioneers in cell
and gene therapy, the Company has more than 25 years of experience
in viral vectors; the driving force behind the majority of gene
therapies. The Company collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg,
France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.